Steven Robert Martin - 23 Jun 2022 Form 4 Insider Report for Ensysce Biosciences, Inc. (ENSC)

Reporting relationship: Director
Issuer ticker: ENSC
Reported as of: 23 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Jun 2022, 17:44:36 UTC
Prior SEC filing: 04 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ Steve R. Martin

Key filing fact

Steven Robert Martin filed Form 4 for Ensysce Biosciences, Inc. (ENSC) on 27 Jun 2022.

Key facts

This page summarizes Steven Robert Martin's Form 4 filing for Ensysce Biosciences, Inc. (ENSC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 27 Jun 2022, 17:44.

Change

Previous filing in this sequence was filed on 04 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ENSC transaction Derivative

Stock Option

Award

Transaction value
Shares: +15,000
Change %: +17%
Price
Shares after: 100,850
Date: 23 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $0.4250
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On June 23, 2022, Mr. Martin was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.